This catalog entry combines BPC-157, GHK-CU, and TB-500, three peptides that show up in experimental and wellness discussions around tissue repair, cosmetic applications, and anti-inflammatory themes.

The combination SKU is organizational: it indicates that these peptides are packaged together, not that combined use is supported by strong clinical evidence or professional guidelines.

At a high level, combination products like this aim to bundle multiple mechanistic ideas:

• BPC-157: discussed in preclinical work for potential effects on vascular, inflammatory, and gastrointestinal integrity

• TB-500 (thymosin beta-4 fragment): associated in models with actin dynamics, cell migration, and tissue repair

• GHK-CU: a copper-binding peptide often referenced in cosmetic and wound- healing contexts

The actual clinical significance of combining all three in humans is not well defined, and rigorous combination studies are limited.

In most regulated settings, these peptides—alone or in combination—do not have approved indications for tissue repair, cosmetic, or anti-inflammatory use. They are more commonly encountered in research channels or grey-market wellness spaces.

Any proposed use of combination products should be approached as experimental and evaluated carefully against local laws and ethical standards.

Described effects for single agents include local injection-site reactions, gastrointestinal symptoms, headache, and nonspecific fatigue. Long-term safety, especially with multi-peptide regimens, is poorly characterized.

Because of these gaps, conservative interpretation and reliance on up-to-date, peer-reviewed evidence are especially important.

This blend combines tissue repair peptides. Dosing is often calculated based on the BPC-157 content.

This information summarizes commonly discussed research practices.

Catalog listings for BPC-157 + GHK-CU + TB-500 typically describe total milligram content and vial counts. These details clarify structure and packaging, not clinical appropriateness.

Most systematic work examines BPC-157, thymosin beta-4–related peptides, and GHK-CU separately. Formal evidence on triple combinations is sparse.

As a result, high-level summaries like this are best used as orientation to concepts, not as a basis for recommending combination use.

Future FAQs may address why multi-peptide blends are marketed, what kinds of data would strengthen or weaken confidence in such products, and how clinicians think about layering mechanisms versus keeping regimens simple. Answers will remain educational and non-prescriptive.